Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice
- PMID: 16006012
- DOI: 10.1016/j.neurobiolaging.2005.04.010
Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice
Abstract
In addition to genetic factors, environmental factors have long been suspected to contribute to the pathogenesis of Parkinson's disease (PD). We investigated the possible interaction between genetic factors and neurotoxins by testing whether alpha-synuclein A30P Tg5093 transgenic mice show increased sensitivity to secondary toxic insults like 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or rotenone. While sensitivity to chronic treatment with rotenone was not enhanced in the Tg5093 line, chronic treatment with 80 or 150 mg/kg MPTP resulted in increased deterioration of the nigrostriatal dopaminergic system as assessed by quantitation of nigral tyrosine hydroxylase (TH) positive neurons and striatal dopamine (DA) levels in Tg5093 mice when compared to non-transgenic littermate controls. Thus, the results of this study demonstrate a role for the overexpression of mutant human alpha-synuclein A30P in increased vulnerability of DA neurons to MPTP.
Similar articles
-
Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.J Neurobiol. 2002 Oct;53(1):1-10. doi: 10.1002/neu.10094. J Neurobiol. 2002. PMID: 12360578
-
Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.Neurotoxicology. 2004 Sep;25(5):761-9. doi: 10.1016/j.neuro.2004.05.002. Neurotoxicology. 2004. PMID: 15288507
-
Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.Neurosci Lett. 2008 Dec 26;448(2):184-8. doi: 10.1016/j.neulet.2008.10.070. Epub 2008 Oct 25. Neurosci Lett. 2008. PMID: 18977411
-
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. doi: 10.2174/187152710791556177. CNS Neurol Disord Drug Targets. 2010. PMID: 20522009 Review.
-
Animal models of neurological disease.Adv Exp Med Biol. 2010;671:23-40. doi: 10.1007/978-1-4419-5819-8_3. Adv Exp Med Biol. 2010. PMID: 20455493 Review.
Cited by
-
Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.Environ Health Perspect. 2011 Jun;119(6):807-14. doi: 10.1289/ehp.1003013. Epub 2011 Jan 18. Environ Health Perspect. 2011. PMID: 21245015 Free PMC article.
-
Current perspective of mitochondrial biology in Parkinson's disease.Neurochem Int. 2018 Jul;117:91-113. doi: 10.1016/j.neuint.2018.03.001. Epub 2018 Mar 14. Neurochem Int. 2018. PMID: 29550604 Free PMC article. Review.
-
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.Front Aging Neurosci. 2010 May 21;2:17. doi: 10.3389/fnagi.2010.00017. eCollection 2010. Front Aging Neurosci. 2010. PMID: 20577640 Free PMC article.
-
Aquaporin-4 deficiency reduces TGF-β1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease.J Cell Mol Med. 2019 Apr;23(4):2568-2582. doi: 10.1111/jcmm.14147. Epub 2019 Jan 25. J Cell Mol Med. 2019. PMID: 30680924 Free PMC article.
-
Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.Prog Neurobiol. 2011 Jun;94(1):1-19. doi: 10.1016/j.pneurobio.2011.03.005. Epub 2011 Mar 23. Prog Neurobiol. 2011. PMID: 21439347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases